Skip to content

Zymeworks ZYME All classes of stock, shares authorized (in shares)

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept zyme:AllClassesOfStockSharesAuthorized.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Zymeworks's all classes of stock, shares authorized (in shares)?
Zymeworks (ZYME) reported all classes of stock, shares authorized (in shares) of 1B in Q1 2026.
How has Zymeworks's all classes of stock, shares authorized (in shares) changed year-over-year?
Zymeworks's all classes of stock, shares authorized (in shares) decreased by 0.0% year-over-year, from 1B to 1B.